A Phase 1 interventional study of Losartan and Cozaar® in Healthy, sponsored by Teva Pharmaceuticals USA. Completed at 1 site in Canada. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-08-19.
Sponsored by Teva Pharmaceuticals USA (part of Teva Pharmaceutical Industries, Ltd.) · Phase 1, Interventional, and Other
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The objective of this study is to compare the rate and extent of absorption of losartan 100 mg tablets (test) versus Cozaar® (reference), administered as 1 * 100 mg tablet under fed conditions.
Criteria for Evaluation: FDA Bioequivalence Criteria
Statistical Methods: FDA Bioequivalence Statistical Methods
Teva Pharmaceuticals USA is the lead sponsor of 176 studies on the registry; none are open to participants now.
Of its 5 completed or terminated interventional studies of FDA-regulated products, 4 (80%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Non-child-bearing potential female subject:
Exclusion Criteria:
Donation of plasma (500 mL) within 7 days prior to drug administration. Donation or loss of whole blood prior to administration of study medication as follows:
Additional exclusion criteria for females only:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Losartan 100 mg Tablets
Drug: Losartan
Cozaar® 100 mg Tablets
Drug: Cozaar®
Cmax of Losartan (Maximum Observed Concentration of Drug Substance in Plasma)
Bioequivalence based on Losartan Cmax.
Time frame: Blood samples collected over a 24 hour period.
AUC0-t of Losartan (Area Under the Concentration-time Curve From Time Zero to Time of Last Measurable Concentration)
Bioequivalence based on Losartan AUC0-t.
Time frame: Blood samples collected over a 24 hour period.
AUC0-inf of Losartan (Area Under the Concentration-time Curve From Time Zero to Infinity)
Bioequivalence based on Losartan AUC0-inf.
Time frame: Blood samples collected over a 24 hour period.
Cmax of Losartan Carboxy Acid (Maximum Observed Concentration of Drug Substance in Plasma)
Informational comparison of Cmax values for the metabolite Losartan Carboxy Acid.
Time frame: Blood samples collected over a 24 hour period.
AUC0-t of Losartan Carboxy Acid (Area Under the Concentration-time Curve From Time Zero to Time of Last Measurable Concentration)
Informational comparison of AUC0-t values for the metabolite Losartan Carboxy Acid.
Time frame: Blood samples collected over a 24 hour period.
AUC0-inf or Losartan Carboxy Acid (Area Under the Concentration-time Curve From Time Zero to Infinity)
Informational comparison of AUC0-inf values for the metabolite Losartan Carboxy Acid.
Time frame: Blood samples collected over a 24 hour period.
| Milestone | Losartan (Test) First | Cozaar® (Reference) First |
|---|---|---|
| Started | 40 | 40 |
| Completed | 40 | 40 |
| Not completed | 0 | 0 |
| Milestone | Losartan (Test) First | Cozaar® (Reference) First |
|---|---|---|
| Started | 40 | 40 |
| Completed | 40 | 38 |
| Not completed | 0 | 2 |
| Withdrew: Withdrawal by subject | 0 | 2 |
| Milestone | Losartan (Test) First | Cozaar® (Reference) First |
|---|---|---|
| Started | 40 | 38 |
| Completed | 40 | 38 |
| Not completed | 0 | 0 |
Bioequivalence based on Losartan Cmax.
| ng/mL | Losartan (Test) | Cozaar® (Reference) |
|---|---|---|
| Cmax of Losartan (Maximum Observed Concentration of Drug Substance in Plasma) | 407.66 ± 209.45 | 360.82 ± 183.42 |
Bioequivalence based on Losartan AUC0-t.
| ng*h/mL | Losartan (Test) | Cozaar® (Reference) |
|---|---|---|
| AUC0-t of Losartan (Area Under the Concentration-time Curve From Time Zero to Time of Last Measurable Concentration) | 915.12 ± 271.70 | 864.29 ± 260.73 |
Bioequivalence based on Losartan AUC0-inf.
| ng*h/mL | Losartan (Test) | Cozaar® (Reference) |
|---|---|---|
| AUC0-inf of Losartan (Area Under the Concentration-time Curve From Time Zero to Infinity) | 926.82 ± 274.16 | 877.73 ± 264.17 |
Informational comparison of Cmax values for the metabolite Losartan Carboxy Acid.
| ng/mL | Losartan (Test) | Cozaar® (Reference) |
|---|---|---|
| Cmax of Losartan Carboxy Acid (Maximum Observed Concentration of Drug Substance in Plasma) | 587.80 ± 196.59 | 560.83 ± 210.92 |
Informational comparison of AUC0-t values for the metabolite Losartan Carboxy Acid.
| ng*h/mL | Losartan (Test) | Cozaar® (Reference) |
|---|---|---|
| AUC0-t of Losartan Carboxy Acid (Area Under the Concentration-time Curve From Time Zero to Time of Last Measurable Concentration) | 3556.41 ± 1032.48 | 3453.09 ± 1041.97 |
Informational comparison of AUC0-inf values for the metabolite Losartan Carboxy Acid.
| ng*h/mL | Losartan (Test) | Cozaar® (Reference) |
|---|---|---|
| AUC0-inf or Losartan Carboxy Acid (Area Under the Concentration-time Curve From Time Zero to Infinity) | 3679.30 ± 1065.16 | 3607.01 ± 1119.74 |
Collected over Adverse event data was collected over the course of the study, which was approximately 2 weeks in duration.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Losartan (Test) | — | 0/80 (0%) | 5/80 (6.3%) |
| Cozaar® (Reference) | — | 0/80 (0%) | 3/80 (3.8%) |
| Event | Losartan (Test) | Cozaar® (Reference) |
|---|---|---|
| Low Blood PressureGeneral disorders | 5/80 | 3/80 |
| Age, Categorical(Participants) | Losartan (Test) First | Cozaar® (Reference) First | Total |
|---|---|---|---|
| <=18 years | 0 | 0 | 0 |
| Between 18 and 65 years | 37 | 38 | 75 |
| >=65 years | 3 | 2 | 5 |
| Sex: Female, Male(Participants) | Losartan (Test) First | Cozaar® (Reference) First | Total |
|---|---|---|---|
| Female | 13 | 23 | 36 |
| Male | 27 | 17 | 44 |
| Race/Ethnicity, Customized(participants) | Losartan (Test) First | Cozaar® (Reference) First | Total |
|---|---|---|---|
| Black | 3 | 2 | 5 |
| Caucasian | 36 | 35 | 71 |
| Hispanic | 1 | 3 | 4 |
| Region of Enrollment(participants) | Losartan (Test) First | Cozaar® (Reference) First | Total |
|---|---|---|---|
| Canada | 40 | 40 | 80 |
The record gives a start of Oct 2003, a primary completion of Nov 2003 and a completion of Nov 2003. It does not say whether these dates are actual or estimated.
Results were first posted in Jul 2010, 6 years 8 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Losartan